மார்ச் 9: CAR-T-cell therapy is a novel and effective cancer treatment modality that has revolutionized the treatment of cancer, particularly blood cancers. This therapy achieves a therapeutic effect or cures disease by repairing or reconstructing genetic materials that have been damaged. Since Roseberg first isolated tumour-infiltrating lymphocytes (TILs) to treat melanoma in 1986, the development of modified T cell therapy has gained significant momentum. Since the FDA approved the first CAR-T சிகிச்சை, Kymriah, in 2017, the CAR-T market has grown rapidly. According to Frost & Sullivan, the global CAR-T market size is projected to increase from USD 10 million in 2017 to USD 1.08 billion in 2020, and then to USD 9.05 billion in 2025, with a compound annual growth rate (CAGR) of 55% from 2019 to 2025, making it the fastest-growing segment of the global cell and gene therapies (CGT) market.
CAR-T therapy is one of CGT therapy’s subsegments. On the basis of the origin of T cells, CAR-T therapy can be divided into two categories. Autologous CAR-T-cell therapy, which employs the patient’s own immune cells, and allogeneic CAR-T-cell therapy, which employs T cells from donor blood or occasionally umbilical cord blood,. The majority of CAR-T therapies are autologous CAR T-செல் சிகிச்சைகள், which typically involve the steps outlined below:
நீங்கள் படிக்க விரும்பலாம்: சீனாவில் CAR T செல் சிகிச்சை
1) நோயாளியின் புற இரத்தத்தில் இருந்து T செல்கள் அறுவடை செய்யப்படுகின்றன;
2) Viral vectors such as AAV then modify T cells with CAR genes that are directed against a specific cell-surface protein on cancer cells;
3) The modified CAR-T cells population is expanded according to the patient’s weight;
4) The expanded CAR-T cells are then reinfused back into the patient. The entire manufacturing procedure lasts between one and three weeks and requires GMP compliance in an ultra-clean environment.
CAR-T therapy has reached a level of success that has never been seen before in treating B-cell cancers that are resistant to or refractory to chemotherapy, including R/R, B-ALL, NHL, and MM. The effectiveness of treating solid tumours is also currently under investigation. CD19-targeting and BCMA-targeting CAR-T therapies achieve the greatest clinical success among all CAR-T therapies. Four of the six CAR-T therapies approved by the FDA target CD19, while two target BCMA.
The most significant advantage over small and large molecule drugs is that patients can replace lifelong treatment of chronic disease with a limited number of doses, or even just one.
The United States pioneered the development of the CAR-T industry. However, by the middle of the 2010s, China had learned quickly and was catching up to the United States. Principally, the key drivers can be attributed to the Chinese government’s support for the development of a CGT ecosystem comprised of biotech companies, academics, healthcare providers, investors, and the government. Following the prioritization of biotechnology in the thirteenth five-year plan, the Chinese government emphasized its strategy to accelerate the innovation and development of biotech industries, including cell therapy. In addition, pertinent ministries have issued encouraging action regulations.
2015 இல் மருந்துகள் மற்றும் மருத்துவ சாதனங்களின் மதிப்பீடு, மறுஆய்வு மற்றும் ஒப்புதல் அமைப்பு சீர்திருத்தம் குறித்த மாநில கவுன்சிலின் கருத்துக்கள் வெளியிடப்பட்ட பிறகு, மூலதனச் சந்தையும் செயலில் இறங்கியது. 45% கூட்டு வருடாந்திர வளர்ச்சி விகிதத்தில், சீன செல் சிகிச்சை நிறுவனங்கள் 2.4 மற்றும் 2018 க்கு இடையில் சுமார் USD 2021 பில்லியன் நிதி திரட்டியுள்ளன.
நீங்கள் படிக்க விரும்பலாம்: சீனாவில் CAR T செல் சிகிச்சை செலவு
The number of CAR-T therapy trials in China surpassed those in the United States by 2018 as a result of this thriving ecosystem. As of June 2022, Chinese companies had conducted 342 clinical CAR-T trials. Malignancies in the B lineage were among the most prevalent manifestations. Two கார்-டி products have commercial applications: யெஸ்கார்டா in June 2021 and ரெல்மா-செல் in September 2021, among numerous drug candidates.
Frost & Sullivan இன் கூற்றுப்படி, உள்நாட்டு CAR-T சந்தையானது 0.2 இல் CNY 2021 பில்லியனில் இருந்து 8 இல் CNY 2025 பில்லியனாகவும், பின்னர் 28.9 இல் CNY 2030 பில்லியனாகவும், 45 முதல் 2022 வரை 2030% CAGR இல் அதிகரிக்கும் என எதிர்பார்க்கப்படுகிறது. சீன CAR-T சந்தை இன்னும் ஆரம்ப நிலையில் இருப்பதால், ஒரு வலுவான உந்து சக்தி உள்ளது.
Although the two approved CAR-T products are from Sino-US joint ventures Fosun Kite and JW Terapeutics, domestic players have made breakthroughs and caught up to global players in recent years. Legend Biotech, IASO Biotherapeutics, and CARsgen Therapeutics all obtained NDA approval for their BCMA CAR-T products, establishing them as the leaders in BCMA CAR-T therapy. CD19 CAR-T products are a focus for Juventas Therapeutics, Gracell Biotechnologies, Hrain Biotechnology, ImunoPharm, Shanghai Cell Therapy Group, and numerous domestic companies. Juventas Therapeutics is the leader in Chinese CD19 CAR-T சிகிச்சை now that the NMPA has accepted its NDA for CNCT19. CARsgen Therapeutics is a global leader in solid tumours, and CT041 is the first CAR-T candidate for treating solid tumours to enter Phase II மருத்துவ சோதனைகள். Bioheng Biotech மற்றும் BRL Biotech (சீன: ) புதிய அலோஜெனிக் CAR-T சந்தைகளை உருவாக்குகின்றன.
நீங்கள் படிக்க விரும்பலாம்: சீனாவில் பல மைலோமாவுக்கான CAR T செல் சிகிச்சை
